Mercury Laboratories Ltd () News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{ "main_header": { "sid": 287757, "name": "Mercury Labs", "stock_name": "Mercury Labs", "full_name": "Mercury Laboratories Ltd", "name_url": "stocks-analysis/mercury-labs", "exchange": 0, "exchangecode": "", "primexch": 0, "country_id": 34, "currency": "INR", "cmp": "795.00", "chg": -27, "chgp": "-3.28%", "dir": -1, "prev_price": "822.00", "mcapval": "99.00 Cr", "mcap": "Micro Cap", "scripcode": 538964, "symbol": "", "ind_name": "Pharmaceuticals & Biotechnology", "ind_code": 4, "sector_id": 65, "indexname": "India SENSEX", "isin": "INE947G01011", "curr_date": "Jul 03, 03:30 PM", "curr_time": "16:24 PM", "last_traded_at": "Jul 03, 03:30 PM IST", "bse_nse_vol": "23 ", "exc_status": "Active", "traded_date": "Jul 03, 2026", "traded_date_str": "2026 07 03", "score": "", "scoreText": "", "Live": 0, "market_time": 0, "is_blur": 1, "is_blur_class": "blur-registerF-score-header", "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/mercury-labs-287757-0&utm_source=Spage_Header_Score", "mojoone": { "ismore": 0 } }, "news": { "results": [ { "title": "Mercury Laboratories Ltd Falls 2.21%: Valuation Upgrade and Mixed Weekly Performance", "link": "https://www.marketsmojo.com/news/stocks-in-action/mercury-laboratories-ltd-falls-221-valuation-upgrade-and-mixed-weekly-performance-4089564", "imagepath": "", "date": "2026-07-05 11:00:59", "description": " <div class=\"article-news-new\">\n <div class=\"article-container\">\n\n<div class=\"article-content\">\n <div class=\"highlight-box\">\n <h3>Key Events This Week</h3>\n <p><strong>29 Jun:</strong> Week opens at Rs.813.00</p>\n <p><strong>30 Jun:</strong> Stock drops 3.23% to Rs.786.70 amid volume surge</p>\n <p><strong>1 Jul:</strong> Minor recovery to Rs.790.00 (+0.42%) following rating upgrade announcement</p>\n <p><strong>2 Jul:</strong> Stock rallies 4.05% to Rs.822.00 on improved valuation and technicals</p>\n <p><strong>3 Jul:</strong> Week closes lower at Rs.795.00 (-3.28%) despite Sensex gains</p>\n </div>\n\n <div class=\"stats-row\">\n <div class=\"stat-item\"><div class=\"stat-label\">Week Open</div><div class=\"stat-value\">Rs.813.00</div..." }, { "title": "Mercury Laboratories Ltd Upgraded to Sell on Improved Valuation and Technicals", "link": "https://www.marketsmojo.com/news/stock-recommendation/mercury-laboratories-ltd-upgraded-to-sell-on-improved-valuation-and-technicals-4084205", "imagepath": "https://i.marketsmojo.com/newsimg/2026/7/MercuryLaborato_mojoScore_4084205.png", "date": "2026-07-02 08:25:43", "description": "Mercury Laboratories Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating upgraded from Strong Sell to Sell as of 1 July 2026. This change is primarily driven by a significant improvement in valuation metrics, even as the company’s financial performance remains flat and its long-term fundamentals continue to show weakness." }, { "title": "Mercury Laboratories Ltd Valuation Shifts Signal Renewed Price Attractiveness", "link": "https://www.marketsmojo.com/news/stocks-in-action/mercury-laboratories-ltd-valuation-shifts-signal-renewed-price-attractiveness-4083488", "imagepath": "https://i.marketsmojo.com/newsimg/2026/7/MercuryLaborato_valuationdot_4083488.png", "date": "2026-07-02 08:01:05", "description": "Mercury Laboratories Ltd has witnessed a notable improvement in its valuation parameters, shifting from an attractive to a very attractive rating, despite a challenging sector environment. This micro-cap pharmaceutical player now presents a compelling price proposition relative to its historical averages and peer group, signalling a potential inflection point for investors seeking value in the Pharmaceuticals & Biotechnology sector." }, { "title": "Mercury Laboratories Ltd is Rated Strong Sell", "link": "https://www.marketsmojo.com/news/stock-recommendation/mercury-laboratories-ltd-is-rated-strong-sell-4075774", "imagepath": "https://i.marketsmojo.com/newsimg/2026/6/MercuryLaborato_mojoScore_4075774.png", "date": "2026-06-28 10:10:45", "description": "Mercury Laboratories Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 27 May 2026, reflecting a reassessment of the stock’s outlook. However, all fundamentals, returns, and financial metrics discussed here are current as of 28 June 2026, providing investors with the latest view of the company’s position." }, { "title": "Mercury Laboratories Ltd is Rated Strong Sell", "link": "https://www.marketsmojo.com/news/stock-recommendation/mercury-laboratories-ltd-is-rated-strong-sell-4055854", "imagepath": "https://i.marketsmojo.com/newsimg/2026/6/MercuryLaborato_mojoScore_4055854.png", "date": "2026-06-16 10:11:10", "description": "Mercury Laboratories Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 27 May 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 16 June 2026, providing investors with the latest insights into the company’s performance and outlook." }, { "title": "Mercury Laboratories Ltd Reports Flat Quarterly Performance Amid Margin Pressures", "link": "https://www.marketsmojo.com/news/stocks-in-action/mercury-laboratories-ltd-reports-flat-quarterly-performance-amid-margin-pressures-4024912", "imagepath": "https://i.marketsmojo.com/newsimg/2026/6/MercuryLaborato_fintrenddot_4024912.png", "date": "2026-06-01 08:00:18", "description": "Mercury Laboratories Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has reported a flat financial performance for the quarter ended March 2026, marking a significant shift from its previously positive growth trajectory. Despite a higher profit after tax (PAT) for the nine-month period, the company’s quarterly operating profit and margins have contracted sharply, prompting a downgrade in its Mojo Grade to Strong Sell." }, { "title": "Mercury Laboratories Ltd Gains 3.13%: 3 Key Factors Driving the Week’s Volatility", "link": "https://www.marketsmojo.com/news/stocks-in-action/mercury-laboratories-ltd-gains-313-3-key-factors-driving-the-weeks-volatility-4024459", "imagepath": "", "date": "2026-05-31 11:00:09", "description": " <div class=\"article-news-new\">\n <div class=\"article-container\">\n\n<div class=\"article-content\">\n <div class=\"highlight-box\">\n <h3>Key Events This Week</h3>\n <p><strong>May 25:</strong> Stock rallies 19.99% on upgrade to Sell rating</p>\n <p><strong>May 26:</strong> Valuation shifts to fair amid strong price rally</p>\n <p><strong>May 27:</strong> Downgrade to Strong Sell triggers 6.25% decline</p>\n <p><strong>May 29:</strong> Week closes at Rs.763.45, up 3.13% for the week</p>\n </div>\n\n <div class=\"stats-row\">\n <div class=\"stat-item\"><div class=\"stat-label\">Week Open</div><div class=\"stat-value\">Rs.740.25</div></div>\n <div class=\"stat-item\"><div class=\"stat-label\">Week Close</div><div class=\"stat-value\">Rs.763.45</div><div c..." }, { "title": "Are Mercury Laboratories Ltd latest results good or bad?", "link": "https://www.marketsmojo.com/news/result-analysis/are-mercury-laboratories-ltd-latest-results-good-or-bad-4023833", "imagepath": "", "date": "2026-05-30 19:46:27", "description": "Mercury Laboratories Ltd's latest financial results for the quarter ended March 2026 reveal a complex operational landscape characterized by both revenue growth and profitability challenges. The company reported net sales of ₹20.44 crores, reflecting an 11.39% increase compared to the previous quarter, which contrasts with a slight year-on-year decline of 1.06%. This sequential growth in sales indicates some positive momentum; however, it is overshadowed by a significant contraction in profitability.\n\nNet profit for the same quarter was recorded at ₹1.23 crores, which shows a 23% increase from the previous quarter, yet this figure also represents a year-on-year decrease of 1.06%. The operating margin, a critical indicator of operational efficiency, fell to 9.93%, marking a notable decline from 13.73% in the preceding quarter and indicating pressures on cost management and pricing strategies.\n\nThe operationa..." }, { "title": "Mercury Laboratories Q4 FY26: Profitability Concerns Deepen as Margins Contract Sharply", "link": "https://www.marketsmojo.com/news/result-analysis/mercury-laboratories-q4-fy26-profitability-concerns-deepen-as-margins-contract-sharply-4022628", "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/MercuryLaborato_quaterlyResult_4022628.png", "date": "2026-05-29 20:47:12", "description": "Mercury Laboratories Ltd., a Mumbai-based pharmaceutical company, reported concerning results for Q4 FY26 (January-March 2026), with net profit rising 10.81% quarter-on-quarter to ₹1.23 crores but declining 1.06% year-on-year from ₹1.11 crores. The ₹93.00 crore market capitalisation company faced significant margin pressures as operating profitability deteriorated to its lowest level in recent quarters, raising questions about the sustainability of its business model in an increasingly competitive pharmaceutical landscape." } ], "total": 145, "sid": "287757", "stock_news_url": "https://www.marketsmojo.com/news/mercury-laboratories-287757" }, "announcements": [ { "caption": "Announcement under Regulation 30 (LODR)-Credit Rating", "datetime": "01-Jul-2026", "details": "Intimation regarding Credit Rating on Fixed deposit is attached", "source": "BSE" }, { "caption": "Closure of Trading Window", "datetime": "25-Jun-2026", "details": "Intimation of Closure of Trading window for the announcement of unaudited Financial Results for the quarte ended on June 30 2026 is attached", "source": "BSE" }, { "caption": "Announcement under Regulation 30 (LODR)-Change in Management", "datetime": "11-Jun-2026", "details": "Intimation about the appointment of Plant head is attached", "source": "BSE" } ], "corporate_actions": [ { "img": "board-meeting.svg", "title": "BOARD MEETING", "msg": "<span>No</span> Upcoming Board Meetings", "data": [] }, { "img": "dividend.svg", "title": "DIVIDEND", "msg": "", "data": [ { "txt": "Mercury Laboratories Ltd has declared <strong>35%</strong> dividend, ex-date: 06 Aug 25", "dt": "2025-08-06", "middle_text": "Dividend Alert" } ] }, { "img": "splits.svg", "title": "SPLITS", "msg": "No <strong>Splits</strong> history available", "data": [] }, { "img": "bonus.svg", "title": "BONUS", "msg": "No <strong>Bonus</strong> history available", "data": [] }, { "img": "rights-issues.svg", "title": "RIGHTS", "msg": "No <strong>Rights</strong> history available", "data": [] } ] }

Key Events This Week

29 Jun: Week opens at Rs.813.00

30 Jun: Stock drops 3.23% to Rs.786.70 amid volume surge

1 Jul: Minor recovery to Rs.790.00 (+0.42%) following rating upgrade announcement

2 Jul: Stock rallies 4.05% to Rs.822.00 on improved valuation and technicals

3 Jul: Week closes lower at Rs.795.00 (-3.28%) despite Sensex gains

Week Open

Rs.813.00Read full news article

Mercury Laboratories Ltd Upgraded to Sell on Improved Valuation and Technicals

2026-07-02 08:25:43

Mercury Laboratories Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating upgraded from Strong Sell to Sell as of 1 July 2026. This change is primarily driven by a significant improvement in valuation metrics, even as the company’s financial performance remains flat and its long-term fundamentals continue to show weakness.

Read full news article

Mercury Laboratories Ltd Valuation Shifts Signal Renewed Price Attractiveness

2026-07-02 08:01:05

Mercury Laboratories Ltd has witnessed a notable improvement in its valuation parameters, shifting from an attractive to a very attractive rating, despite a challenging sector environment. This micro-cap pharmaceutical player now presents a compelling price proposition relative to its historical averages and peer group, signalling a potential inflection point for investors seeking value in the Pharmaceuticals & Biotechnology sector.

Read full news article

Mercury Laboratories Ltd is Rated Strong Sell

2026-06-28 10:10:45

Mercury Laboratories Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 27 May 2026, reflecting a reassessment of the stock’s outlook. However, all fundamentals, returns, and financial metrics discussed here are current as of 28 June 2026, providing investors with the latest view of the company’s position.

Read full news article

Mercury Laboratories Ltd is Rated Strong Sell

2026-06-16 10:11:10

Mercury Laboratories Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 27 May 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 16 June 2026, providing investors with the latest insights into the company’s performance and outlook.

Read full news article

Mercury Laboratories Ltd Reports Flat Quarterly Performance Amid Margin Pressures

2026-06-01 08:00:18

Mercury Laboratories Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has reported a flat financial performance for the quarter ended March 2026, marking a significant shift from its previously positive growth trajectory. Despite a higher profit after tax (PAT) for the nine-month period, the company’s quarterly operating profit and margins have contracted sharply, prompting a downgrade in its Mojo Grade to Strong Sell.

Read full news article

Mercury Laboratories Ltd Gains 3.13%: 3 Key Factors Driving the Week’s Volatility

2026-05-31 11:00:09

Key Events This Week

May 25: Stock rallies 19.99% on upgrade to Sell rating

May 26: Valuation shifts to fair amid strong price rally

May 27: Downgrade to Strong Sell triggers 6.25% decline

May 29: Week closes at Rs.763.45, up 3.13% for the week

Read full news article

Are Mercury Laboratories Ltd latest results good or bad?

2026-05-30 19:46:27

Mercury Laboratories Ltd's latest financial results for the quarter ended March 2026 reveal a complex operational landscape characterized by both revenue growth and profitability challenges. The company reported net sales of ₹20.44 crores, reflecting an 11.39% increase compared to the previous quarter, which contrasts with a slight year-on-year decline of 1.06%. This sequential growth in sales indicates some positive momentum; however, it is overshadowed by a significant contraction in profitability. Net profit for the same quarter was recorded at ₹1.23 crores, which shows a 23% increase from the previous quarter, yet this figure also represents a year-on-year decrease of 1.06%. The operating margin, a critical indicator of operational efficiency, fell to 9.93%, marking a notable decline from 13.73% in the preceding quarter and indicating pressures on cost management and pricing strategies. The operationa...

Read full news article

Mercury Laboratories Q4 FY26: Profitability Concerns Deepen as Margins Contract Sharply

2026-05-29 20:47:12

Mercury Laboratories Ltd., a Mumbai-based pharmaceutical company, reported concerning results for Q4 FY26 (January-March 2026), with net profit rising 10.81% quarter-on-quarter to ₹1.23 crores but declining 1.06% year-on-year from ₹1.11 crores. The ₹93.00 crore market capitalisation company faced significant margin pressures as operating profitability deteriorated to its lowest level in recent quarters, raising questions about the sustainability of its business model in an increasingly competitive pharmaceutical landscape.

Read full news article

View All News